SCHEMBL1129219

SCHEMBL1129219

Nc1cccc(Oc2ccc(C3=NC(C4=CC=C4)=C4C=NC=C[N+]34N)cc2)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.36
ALDH1A1 P00352 2/20 0.33
ATM Q13315 1/20 0.33
CHEK2 O96017 1/20 0.32
MEN1 O00255 1/20 0.32
MITF O75030 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
GFER P55789 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NLRP1 Q9C000 1/20 0.32
NOD2 Q9HC29 1/20 0.32
LCK P06239 1/20 0.31
KDR P35968 1/20 0.31
TEK Q02763 1/20 0.31
LTA4H P09960 1/20 0.30
HPSE Q9Y251 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4354313 0.89 CHEK2 (0.34) CHEK2
SCHEMBL4358455 0.89 FFAR4 (0.34)
SCHEMBL4364440 0.89 ALDH1A1 (0.38) ALDH1A1MEN1GAAKMT2A
SCHEMBL4357998 0.89 MGLL (0.32)
SCHEMBL13504709 0.89 SMN1; SMN2 (0.38) ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4363046 0.88 CHEK2 (0.32) CHEK2
SCHEMBL4352044 0.87 CHEK2 (0.37) ALDH1A1CHEK2MAPTLTA4H
SCHEMBL4353738 0.87 TNK2 (0.33)
SCHEMBL4364234 0.87 SCN9A (0.35)
SCHEMBL4369161 0.87 CHEK2 (0.37) CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP claimed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 MAOB 1396/4885ALDH1A1 292/4885ATM 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.